{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:31:42Z","timestamp":1793043102510,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40257-025-00970-8","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:37:43Z","timestamp":1752597463000},"page":"803-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study"],"prefix":"10.1007","volume":"26","clinical-trial-number":[{"clinical-trial-number":"nct05372419","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andrew","family":"Alexis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Moiin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Waibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber Reck","family":"Atwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Proper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Silk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreekumar","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ADmirable Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"970_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"key":"970_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40:84\u201392. https:\/\/doi.org\/10.2500\/aap.2019.40.4202.","journal-title":"Allergy Asthma Proc"},{"key":"970_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41232-017-0044-7","volume":"37","author":"P Rerknimitr","year":"2017","unstructured":"Rerknimitr P, Otsuka A, Nakashima C, et al. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37:14. https:\/\/doi.org\/10.1186\/s41232-017-0044-7.","journal-title":"Inflamm Regen."},{"issue":"5","key":"970_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40257-023-00797-1","volume":"24","author":"VL Quan","year":"2023","unstructured":"Quan VL, Erickson T, Daftary K, et al. Atopic dermatitis across shades of skin. Am J Clin Dermatol. 2023;24(5):731\u201351. https:\/\/doi.org\/10.1007\/s40257-023-00797-1.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"970_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s13671-014-0097-7","volume":"4","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI. Racial and ethnic disparities in atopic dermatitis. Curr Dermatol Rep. 2015;4(1):44\u20138. https:\/\/doi.org\/10.1007\/s13671-014-0097-7.","journal-title":"Curr Dermatol Rep"},{"issue":"1","key":"970_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, et al. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1\u201311. https:\/\/doi.org\/10.1016\/j.jaci.2018.10.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"970_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.36849\/jdd.6609","volume":"21","author":"A Alexis","year":"2022","unstructured":"Alexis A, Woolery-Lloyd H, Andriessen A, et al. Insights in skin of color patients with atopic dermatitis and the role of skincare in improving outcomes. J Drugs Dermatol. 2022;21(5):462\u201370. https:\/\/doi.org\/10.36849\/jdd.6609.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"970_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000504911","volume":"237","author":"KN Price","year":"2021","unstructured":"Price KN, Hsiao JL, Shi VY. Race and ethnicity gaps in global hidradenitis suppurativa clinical trials. Dermatology. 2021;237(1):97\u2013102. https:\/\/doi.org\/10.1159\/000504911.","journal-title":"Dermatology"},{"issue":"3","key":"970_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jamadermatol.2021.5596","volume":"158","author":"V Chen","year":"2022","unstructured":"Chen V, Akhtar S, Zheng C, et al. Assessment of changes in diversity in dermatology clinical trials between 2010\u20132015 and 2015\u20132020: a systematic review. JAMA Dermatol. 2022;158(3):288\u201392. https:\/\/doi.org\/10.1001\/jamadermatol.2021.5596.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"970_CR10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jaci.2021.09.015","volume":"148","author":"EA Croce","year":"2021","unstructured":"Croce EA, Levy ML, Adamson AS, et al. Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations. J Allergy Clin Immunol. 2021;148(5):1104\u201311. https:\/\/doi.org\/10.1016\/j.jaci.2021.09.015.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"970_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","volume":"122","author":"PM Brunner","year":"2019","unstructured":"Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(5):449\u201355. https:\/\/doi.org\/10.1016\/j.anai.2018.11.015.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"970_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15914","author":"S Gottlieb","year":"2025","unstructured":"Gottlieb S, Madkins K, Lio P. An Updated Scoping Review of Disparities in Pediatric Atopic Dermatitis. Pediatr Dermatol. 2025. https:\/\/doi.org\/10.1111\/pde.15914. (Epub ahead of print. PMID: 40166858).","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"970_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jaad.2005.10.068","volume":"55","author":"T Ebede","year":"2006","unstructured":"Ebede T, Papier A. Disparities in dermatology educational resources. J Am Acad Dermatol. 2006;55(4):687\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2005.10.068.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"970_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jaad.2020.04.084","volume":"84","author":"A Adelekun","year":"2021","unstructured":"Adelekun A, Onyekaba G, Lipoff JB. Skin color in dermatology textbooks: an updated evaluation and analysis. J Am Acad Dermatol. 2021;84(1):194\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.084.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"970_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.clindermatol.2021.11.015","volume":"40","author":"MK Ibraheim","year":"2022","unstructured":"Ibraheim MK, Gupta R, Dao H, et al. Evaluating skin of color education in dermatology residency programs: data from a national survey. Clin Dermatol. 2022;40(2):228\u201333. https:\/\/doi.org\/10.1016\/j.clindermatol.2021.11.015.","journal-title":"Clin Dermatol"},{"issue":"3","key":"970_CR16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jaad.2021.03.036","volume":"86","author":"A Kurtti","year":"2022","unstructured":"Kurtti A, Austin E, Jagdeo J. Representation of skin color in dermatology-related Google image searches. J Am Acad Dermatol. 2022;86(3):705\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.036.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"970_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijwd.2015.05.002","volume":"1","author":"CY Zhao","year":"2015","unstructured":"Zhao CY, Wijayanti A, Doria MC, et al. The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: a grey area. Int J Womens Dermatol. 2015;1(3):150\u20134. https:\/\/doi.org\/10.1016\/j.ijwd.2015.05.002.","journal-title":"Int J Womens Dermatol."},{"issue":"12","key":"970_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2206714.","journal-title":"N Engl J Med"},{"issue":"6","key":"970_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad022.","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"970_CR20","doi-asserted-by":"publisher","first-page":"ii20","DOI":"10.1093\/bjd\/ljad498.024","volume":"190","author":"A Alexis","year":"2024","unstructured":"Alexis A, Ardern-Jones M, Chovatiya R, et al. Lebrikizumab demonstrates significant efficacy versus placebo across racial and ethnic subgroups in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2024;190(Suppl 2):ii20\u20131. https:\/\/doi.org\/10.1093\/bjd\/ljad498.024.","journal-title":"Br J Dermatol"},{"issue":"2","key":"970_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","volume":"70","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2013.10.010.","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"970_CR22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"JAMA"},{"issue":"1","key":"970_CR23","doi-asserted-by":"publisher","first-page":"s514","DOI":"10.25251\/skin.9.supp.514","volume":"9","author":"A Alexis","year":"2025","unstructured":"Alexis A, Pierce E, Cohee A, et al. Assessing post-inflammatory pigmentation in atopic dermatitis: reliability of the PDCA-Derm\u2122. J Skin. 2025;9(1):s514. https:\/\/doi.org\/10.25251\/skin.9.supp.514.","journal-title":"J Skin"},{"issue":"8","key":"970_CR24","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/j.1398-9995.2011.02577.x","volume":"66","author":"JF Stalder","year":"2011","unstructured":"Stalder JF, Barbarot S, Wollenberg A, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011;66(8):1114\u201321. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02577.x.","journal-title":"Allergy"},{"issue":"4","key":"970_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/jdv.15999","volume":"34","author":"O Faye","year":"2020","unstructured":"Faye O, Meledie N\u2019Djong AP, Diadie S, et al. Validation of the Patient-Oriented SCORing for Atopic Dermatitis tool for black skin. J Eur Acad Dermatol Venereol. 2020;34(4):795\u20139. https:\/\/doi.org\/10.1111\/jdv.15999.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"970_CR26","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jaad.2023.08.103","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):342\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.103.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"970_CR27","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00403-022-02507-z","volume":"315","author":"S Narla","year":"2023","unstructured":"Narla S, Heath CR, Alexis A, et al. Racial disparities in dermatology. Arch Dermatol Res. 2023;315(5):1215\u201323. https:\/\/doi.org\/10.1007\/s00403-022-02507-z. (Ref #8 in this: Bureau UC. Projections of the size and composition of the U.S. population. In: Bureau UC, ed2015).","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"970_CR28","first-page":"804","volume":"18","author":"AF Alexis","year":"2019","unstructured":"Alexis AF, Rendon M, Silverberg JI, et al. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials. J Drugs Dermatol. 2019;18(8):804\u201313.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"970_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","volume":"159","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159(2):182\u201391. https:\/\/doi.org\/10.1001\/jamadermatol.2022.5534.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"970_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2017.01.036","volume":"77","author":"S Chaowattanapanit","year":"2017","unstructured":"Chaowattanapanit S, Silpa-Archa N, Kohli I, et al. Postinflammatory hyperpigmentation: a comprehensive overview: Treatment options and prevention. J Am Acad Dermatol. 2017;77(4):607\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.036.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"970_CR31","first-page":"387","volume":"80","author":"AF Alexis","year":"2007","unstructured":"Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80(5):387\u201394.","journal-title":"Cutis"},{"issue":"4","key":"970_CR32","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jaad.2017.05.009","volume":"77","author":"MBC Maymone","year":"2017","unstructured":"Maymone MBC, Neamah HH, Wirya SA, et al. The impact of skin hyperpigmentation and hyperchromia on quality of life: a cross-sectional study. J Am Acad Dermatol. 2017;77(4):775\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2017.05.009.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"970_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2310\/7750.2009.08077","volume":"13","author":"S Taylor","year":"2009","unstructured":"Taylor S, Grimes P, Lim J, et al. Postinflammatory hyperpigmentation. J Cutan Med Surg. 2009;13(4):183\u201391. https:\/\/doi.org\/10.2310\/7750.2009.08077.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"970_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/ajd.14432","volume":"66","author":"K Mar","year":"2025","unstructured":"Mar K, Maazi M, Khalid B, et al. Prevention of post-inflammatory hyperpigmentation in skin of colour: a systematic review. Australas J Dermatol. 2025;66(3):119\u201326. https:\/\/doi.org\/10.1111\/ajd.14432.","journal-title":"Australas J Dermatol"},{"key":"970_CR35","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/CCID.S385162","volume":"15","author":"E Markiewicz","year":"2022","unstructured":"Markiewicz E, Karaman-Jurukovska N, Mammone T, et al. Post-inflammatory hyperpigmentation in dark skin: molecular mechanism and skincare implications. Clin Cosmet Investig Dermatol. 2022;15:2555\u201365. https:\/\/doi.org\/10.2147\/CCID.S385162.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"970_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/jid.1965.160","volume":"45","author":"CM Papa","year":"1965","unstructured":"Papa CM, Kligman AM. The behavior of melanocytes in inflammation. J Invest Dermatol. 1965;45(6):465\u201373.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"970_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.36849\/JDD.2020.4937","volume":"19","author":"C Grayson","year":"2020","unstructured":"Grayson C, Heath CR. Dupilumab Improves Atopic Dermatitis and Post-Inflammatory Hyperpigmentation in Patient With Skin of Color. J Drugs Dermatol. 2020;19(7):776\u20138. https:\/\/doi.org\/10.36849\/JDD.2020.4937.","journal-title":"J Drugs Dermatol"},{"key":"970_CR38","doi-asserted-by":"publisher","first-page":"6218587","DOI":"10.1155\/2023\/6218587","volume":"2023","author":"HJ Ahn","year":"2023","unstructured":"Ahn HJ, Shin MK. Improvement of Nonlesional Skin Tone and Skin Barrier in Severe Atopic Dermatitis after Dupilumab Treatment. Dermatol Ther. 2023;2023:6218587. https:\/\/doi.org\/10.1155\/2023\/6218587.","journal-title":"Dermatol Ther"},{"issue":"5","key":"970_CR39","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/bjd\/ljae494","volume":"192","author":"C Hartford","year":"2025","unstructured":"Hartford C, Alexis A, Wang Z, et al. Development of novel patient-reported outcome instruments to assess atopic dermatitis-associated dyspigmentation and xerosis in patients with skin of colour. Br J Dermatol. 2025;192(5):863\u201373. https:\/\/doi.org\/10.1093\/bjd\/ljae494.","journal-title":"Br J Dermatol"},{"issue":"8","key":"970_CR40","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1001\/archpediatrics.2009.78","volume":"163","author":"M Morgenstern","year":"2009","unstructured":"Morgenstern M, Sargent JD, Hanewinkel R. Relation between socioeconomic status and body mass index: evidence of an indirect path via television use. Arch Pediatr Adolesc Med. 2009;163(8):731\u20138. https:\/\/doi.org\/10.1001\/archpediatrics.2009.78.","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"3","key":"970_CR41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s13679-020-00398-7","volume":"9","author":"CV Anekwe","year":"2020","unstructured":"Anekwe CV, Jarrell AR, Townsend MJ, et al. Socioeconomics of obesity. Curr Obes Rep. 2020;9(3):272\u20139. https:\/\/doi.org\/10.1007\/s13679-020-00398-7.","journal-title":"Curr Obes Rep"},{"issue":"2","key":"970_CR42","first-page":"77","volume":"105","author":"OR Ware","year":"2020","unstructured":"Ware OR, Dawson JE, Shinohara MM, et al. Racial limitations of fitzpatrick skin type. Cutis. 2020;105(2):77\u201380.","journal-title":"Cutis"},{"issue":"1","key":"970_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/bjd.21277","volume":"187","author":"OE Dadzie","year":"2022","unstructured":"Dadzie OE, Sturm RA, Fajuyigbe D, et al. The Eumelanin Human Skin Colour Scale: a proof-of-concept study. Br J Dermatol. 2022;187(1):99\u2013104. https:\/\/doi.org\/10.1111\/bjd.21277.","journal-title":"Br J Dermatol"},{"issue":"5","key":"970_CR44","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1046\/j.1365-2133.2002.04965.x","volume":"147","author":"MA Ben-Gashir","year":"2002","unstructured":"Ben-Gashir MA, Hay RJ. Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts. Br J Dermatol. 2002;147(5):920\u20135. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04965.x.","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00970-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00970-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00970-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:03:10Z","timestamp":1757966590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00970-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["970"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00970-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"6 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ADmirable clinical trial was conducted in accordance with ethical principles outlined in the Declaration of Helsinki, Council for International Organizations of Medical Sciences, and Good Clinical Practice guidelines. The ADmirable trial protocol was approved by the Advarra Institutional Review Board on 17 October 2022 (IRB #: Pro00066938). Additionally, Advarra approved the study at each participating center (Supplement 1, Table\n                      \n                      ). All investigation sites received approval from the appropriate authorized institutional review board or ethics committee. The ADmirable study is registered on ClinicalTrials.gov (NCT05372419).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all patients before study procedures were initiated. For patients considered to be minors, the written consent of the parent or legal guardian, as well as the assent of the minor, was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figures\n                      \n                      a, 3b, and 3c.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"This study was funded by Eli Lilly and Company. Eli Lilly and Company had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Almirall, S.A. has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe. Lilly has exclusive rights for development and commercialization of lebrikizumab in the United States and the rest of the world outside of Europe.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding and Role of the Funder\/Sponsor"}},{"value":"Andrew Alexis has received grant support (funds to institution) from Leo, Amgen, Galderma, Arcutis, Dermavant, Abbvie, Castle Advisory board\/Consulting: Leo, Galderma, Pfizer, Sanofi-Regeneron, Genzyme, Dermavant, Beiersdorf, Ortho, L\u2019Or\u00e9al, BMS, Bausch health, UCB, Arcutis, Janssen, Allergan, Almirall, Abbvie, Amgen, VisualDx, Eli Lilly and Company, Swiss American, Cutera, Cara, EPI, Incyte, Castle, Apogee, Canfield, Alphyn, Avita Medical, Genentech; has served as a speaker for Regeneron, SANOFI-Genzyme, BMS, L\u2019Oreal, Janssen, and J&J; has received royalties from Springer, Wiley-Blackwell, Wolters Kluwer Health; and has received equipment from Aerolase. Ali Moiin has received reimbursement for travel costs from and conducted clinical trials for Eli Lilly and Company. Jill Waibel has served as a consultant, investigator, and\/or on scientific advisory boards for Allergan (Consultant), Amgen (Clinical Trial), ArgenX (Clinical Trial), Bellamia (Advisory Board), Bristol Myers Squibb (Clinical Trial), Candela (Speaker, Consultant, Advisory Board), Cytrellis Biosystems (Advisory Board, Consultant, Clinical Trial), Eli Lilly and Company (Clinical Trial, Speaker), Emblation (Clinical Trial), Galderma (Clinical Trial, Consultant), Horizon (Clinical Trial), Janssen\/J&J (Clinical Trial), Lumenis (Advisory Board, Consultant, Speaker), Neuronetics (Clinical Trial), Pfizer (Clinical Trial), P & G (Consultant), RegenX (Clinical Consultant, Clinical Trial, Board of Directors), Sanofi (Clinical Trial), Skinceuticals (Clinical Trial, Consultant, Advisory Board), and Shanghai Biopharma, PWB (Clinical Trial); and has received a VA Merit Grant for Amputated Veterans. Paul Wallace has served as a principal investigator, advisor and\/or speaker for Abbvie, Amgen, Arcutis, Biogen, Bristol Myers, Celgene, Centocor, Cynosure, Eli Lilly and Company, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi-Aventis, and UCB; and has received equipment (loan to institution) from Cynosure. David Cohen reports no financial conflicts of interest. Vivian Laquer conducts research for Abbvie, Acelyrin, Acrotech, Amgen, Argenx, Arcutis, Aslan, Biofrontera, Bristol Meyers Squibb, Cara, Dermavant, Eli Lilly and Company, Galderma, Horizon Therapeutics, Incyte, Janssen, Leo, Novartis, Padagis, Pfizer, Q32, Rapt, Sun, UCB, and Ventyx. Pearl Kwong is a principal investigator for Eli Lilly and Company, Pfizer, Dermavant, Incyte, Arcutis, Galderma, Novartis, Abbvie, CastleCreek Biosciences, Amgen, and UCB; a consultant\/advisor for Leo, Galderma, Pfizer, Eli Lilly and Company, Incyte, EPI Health, Novan, Verrica, BMS, Sanofi-Regeneron, UCB, and Ortho; and a speaker for Abbvie, Regeneron Sanofi, Incyte, Verrica, Sun Pharma, Ortho, L\u2019Or\u00e9al, EPI, and Arcutis. Amber Reck Atwater is a former employee of Eli Lilly and Company. Jennifer Proper, Evangeline Pierce, Christopher Schuster, Maria Silk, Sreekumar Pillai, and Maria Jose Rueda are employees and shareholders of Eli Lilly and Company. Angela Moore has received research grants or honoraria from Abbvie, Acrotech, Arcutis, Bristol Meyers Squibb, Cara, Eli Lilly and Company, Galderma, Incyte, Janssen J&J, Pfizer, Rapt, and Sanofi-Regeneron.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"A. Alexis has contributed to conception of the study and interpretation of the data. A. Moiin has contributed to conception of the work. A. Moore, J. Waibel, and P. Wallace have contributed to acquisition and interpretation of data. D. Cohen and V. Laquer have contributed to acquisition of data. P. Kwong has contributed to interpretation of data. A. Atwater, M. Silk, E. Pierce, S. Pillai, and M.J. Rueda have contributed to study conception, design, analysis, and data interpretation. J. Proper has contributed to study analysis and interpretation. C. Schuster has contributed to data interpretation. All authors contributed to the drafting or critical review of the manuscript and give final approval of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contribution"}},{"value":"Initial baseline characteristics were presented at Maui Derm for Dermatologists, 22 January 2024, Maui, USA. An interim analysis of the results was presented at the American Academy of Dermatology Annual Meeting, 10 March 2024, San Diego, USA. Primary results were presented at the Fall Clinical Dermatology Conference, 24 October 2024, Las Vegas, USA. The 24-week results were presented at the Revolutionizing Atopic Dermatitis (RAD) Conference 2025, June 7, 2025, Nashville, USA.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior Meeting Presentation"}},{"value":"Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at\n                      \n                      .","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}